While breast cancer is a high-profile disease, receiving significant private and public research funding and focused awareness and prevention initiatives, patients with metastatic breast cancer face unique challenges. ACCC has identified these 6 effective principles for patient support.
(Myriad) Feb 17, 2017 - Myriad Genetics, Inc., a l
(AstraZeneca) Feb 17, 2017 - Lynparza provided a statistically-significant improvement in progression-free survival compared to ch
(PMLiVE [UK]) Feb 17, 2017 - PARP inhibitor showed “statistically-significant and clinically-meaningful” improvement in phase III trial.
(The Telegraph [UK]) Feb 17, 2017 - Lynparza, part of a new breed of cancer treatments known as Parp inhibitors or DN
Sign up to receive the latest on the ACCC Metastatic Breast Cancer Project